Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peanut allergen proteins are a group of structurally diverse proteins from Arachis hypogaea that elicit IgE-mediated hypersensitivity; at least 12 allergens (Ara h 1–Ara h 13 with gaps) are recognized by the IUIS Allergen Nomenclature Sub-Committee and fall mainly into the cupin superfamily (Ara h 1, Ara h 3), prolamin superfamily/2S albumins (Ara h 2, Ara h 6, Ara h 7, Ara h 9), profilin family (Ara h 5), Bet v 1-related/PR-10 proteins (Ara h 8), oleosins (Ara h 10, Ara h 11), and plant defensins (Ara h 12, Ara h 13)[1][3]. Among these, Ara h 2 is a major and highly potent allergen recognized by approximately 80–90% of peanut-allergic patients, with a five-helix bundle fold stabilized by four disulfide bonds typical of the prolamin superfamily, and its epitope diversity helps distinguish subpopulations of patients based on IgE binding patterns[2]. Collectively, these allergens’ biological roles include seed nutrient storage, plant defense, lipid body stabilization, and cytoskeletal regulation, but clinically they are relevant as triggers of peanut allergy and anaphylaxis and as components used in component-resolved diagnostics to stratify true peanut allergy (e.g., Ara h 2, Ara h 6) versus pollen-related cross-reactivity (e.g., Ara h 8, Ara h 5)[1][3].
Not applicable for drugs directly targeting these allergens; current therapeutics (e.g., oral immunotherapy, epicutaneous immunotherapy, monoclonal anti-IgE) act on the immune system rather than directly on peanut proteins
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peanut allergen proteins (Ara h allergens (collective)).